54.13
price down icon0.35%   -0.19
pre-market  Pre-mercato:  54.55   0.42   +0.78%
loading
Precedente Chiudi:
$54.32
Aprire:
$54.275
Volume 24 ore:
1.49M
Relative Volume:
0.47
Capitalizzazione di mercato:
$4.92B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-19.33
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
-6.01%
1M Prestazione:
-16.41%
6M Prestazione:
+21.61%
1 anno Prestazione:
+11.17%
Intervallo 1D:
Value
$53.68
$55.13
Intervallo di 1 settimana:
Value
$51.80
$57.39
Portata 52W:
Value
$30.04
$71.13

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name
Nome
Crispr Therapeutics Ag
Name
Telefono
(617) 315-4600
Name
Indirizzo
BAARERSTRASSE 14, ZUG
Name
Dipendente
393
Name
Cinguettio
@crisprtx
Name
Prossima data di guadagno
2024-12-05
Name
Ultimi documenti SEC
Name
CRSP's Discussions on Twitter

Confronta CRSP con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRSP
Crispr Therapeutics Ag
54.13 5.24B 170.10M -239.59M -191.20M -2.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
388.94 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.38 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
443.64 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
677.32 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
308.63 37.96B 3.81B -644.79M -669.77M -6.24

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-14 Aggiornamento Evercore ISI In-line → Outperform
2025-02-12 Aggiornamento TD Cowen Sell → Hold
2025-02-03 Iniziato H.C. Wainwright Buy
2024-08-06 Reiterato Needham Buy
2024-08-02 Iniziato Rodman & Renshaw Buy
2024-06-28 Ripresa Guggenheim Neutral
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-12-11 Downgrade TD Cowen Market Perform → Underperform
2023-10-17 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-09-27 Iniziato Mizuho Buy
2023-08-17 Aggiornamento Citigroup Neutral → Buy
2023-05-30 Iniziato William Blair Outperform
2023-04-13 Iniziato Cantor Fitzgerald Overweight
2023-03-21 Iniziato Bernstein Mkt Perform
2023-03-17 Iniziato Bryan Garnier Buy
2023-03-07 Iniziato Robert W. Baird Neutral
2022-10-11 Iniziato Morgan Stanley Underweight
2022-08-09 Downgrade Barclays Overweight → Equal Weight
2022-06-23 Downgrade Evercore ISI Outperform → In-line
2022-06-17 Iniziato BMO Capital Markets Outperform
2022-04-28 Iniziato Credit Suisse Neutral
2021-12-07 Iniziato Cowen Market Perform
2021-10-19 Iniziato SVB Leerink Outperform
2021-06-14 Aggiornamento Citigroup Sell → Neutral
2021-04-21 Aggiornamento Jefferies Hold → Buy
2021-03-04 Iniziato JMP Securities Mkt Outperform
2020-12-10 Reiterato Chardan Capital Markets Buy
2020-12-10 Downgrade Jefferies Buy → Hold
2020-12-10 Reiterato Needham Buy
2020-12-07 Downgrade Wells Fargo Overweight → Equal Weight
2020-10-23 Iniziato RBC Capital Mkts Sector Perform
2020-10-05 Iniziato BofA Securities Buy
2020-07-28 Reiterato Needham Buy
2020-07-14 Iniziato SunTrust Buy
2020-06-15 Reiterato Canaccord Genuity Buy
2020-03-05 Iniziato Stifel Hold
2020-02-03 Downgrade Evercore ISI Outperform → In-line
2019-11-19 Aggiornamento William Blair Mkt Perform → Outperform
2019-11-12 Aggiornamento Oppenheimer Perform → Outperform
2019-08-01 Iniziato Jefferies Buy
2019-07-26 Iniziato Canaccord Genuity Buy
2019-06-10 Iniziato ROTH Capital Buy
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-14 Iniziato William Blair Mkt Perform
2019-01-28 Downgrade Goldman Buy → Neutral
2019-01-22 Downgrade Citigroup Neutral → Sell
Mostra tutto

Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie

pulisher
Aug 20, 2025

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN

Aug 20, 2025
pulisher
Aug 20, 2025

Watch for Trend Continuation in CRISPR Therapeutics AG Next WeekJuly 2025 Rallies & Free AI Powered Buy and Sell Recommendations - thegnnews.com

Aug 20, 2025
pulisher
Aug 20, 2025

Vestmark Advisory Solutions Inc. Sells 18,728 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Aug 20, 2025
pulisher
Aug 19, 2025

Bernstein Remains a Hold on Crispr Therapeutics AG (CRSP) - The Globe and Mail

Aug 19, 2025
pulisher
Aug 19, 2025

Fox Run Management L.L.C. Acquires New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Aug 19, 2025
pulisher
Aug 18, 2025

CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

What Makes Crispr Therapeutics Ag (CRSP) a Good Buy? - Yahoo Finance

Aug 18, 2025
pulisher
Aug 18, 2025

EverSource Wealth Advisors LLC Purchases 84,708 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Aug 18, 2025
pulisher
Aug 18, 2025

CRISPR-based therapies signal a new direction in tackling infectious diseases - Clinical Trials Arena

Aug 18, 2025
pulisher
Aug 18, 2025

CRISPR Therapeutics AG Shows Support at Fibonacci Level2025 Key Highlights & Expert-Curated Trade Recommendations - sundaytimes.kr

Aug 18, 2025
pulisher
Aug 17, 2025

Virtu Financial LLC Purchases New Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Aug 17, 2025
pulisher
Aug 17, 2025

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - MSN

Aug 17, 2025
pulisher
Aug 17, 2025

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns - Yahoo Finance

Aug 17, 2025
pulisher
Aug 16, 2025

Benjamin Edwards Inc. Purchases 5,853 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Aug 16, 2025
pulisher
Aug 16, 2025

Pattern Scan Adds CRISPR Therapeutics AG to WatchlistPrice Action & Weekly Breakout Stock Alerts - kangso.co.kr

Aug 16, 2025
pulisher
Aug 16, 2025

Crispr Therapeutics AG: Stock Surge Amid Clinical Advances - TipRanks

Aug 16, 2025
pulisher
Aug 16, 2025

Is CRISPR Therapeutics' (CRSP) Rising Net Loss a Sign of Bold Investment or Growing Pressure? - Yahoo Finance

Aug 16, 2025
pulisher
Aug 15, 2025

Crispr Therapeutics shares rise 1.48% premarket after ReproCELL Incorporated receives ¥5.3 million in funding. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Equities Analysts Offer Predictions for CRSP Q4 Earnings - MarketBeat

Aug 15, 2025
pulisher
Aug 14, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Aug 14, 2025
pulisher
Aug 14, 2025

Crispr Therapeutics shares rise 3.12% intraday after Allogene Therapeutics' positive trial updates. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025 - Seeking Alpha

Aug 14, 2025
pulisher
Aug 14, 2025

Blair William & Co. IL Cuts Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Aug 14, 2025
pulisher
Aug 13, 2025

CRISPR Therapeutics Bets Big On Gene-Editing Breakthroughs - Finimize

Aug 13, 2025
pulisher
Aug 13, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Cetera Investment Advisers - MarketBeat

Aug 13, 2025
pulisher
Aug 13, 2025

Crispr Therapeutics Faces Stock Dip Amid Promising Developments - MSN

Aug 13, 2025
pulisher
Aug 13, 2025

Crispr Therapeutics shares rise 1.10% premarket after Metagenomi reported positive business updates and financial results. - AInvest

Aug 13, 2025
pulisher
Aug 12, 2025

Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Chardan Capital Has Strong Estimate for CRSP FY2026 Earnings - MarketBeat

Aug 12, 2025
pulisher
Aug 12, 2025

Westwood Holdings Group Inc. Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Aug 12, 2025
pulisher
Aug 11, 2025

Research Analysts Issue Forecasts for CRSP FY2025 Earnings - MarketBeat

Aug 11, 2025
pulisher
Aug 11, 2025

3 Monster Stocks in the Making to Buy Right Now - AOL.com

Aug 11, 2025
pulisher
Aug 10, 2025

Barclays Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat

Aug 10, 2025
pulisher
Aug 10, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at HC Wainwright - MarketBeat

Aug 10, 2025
pulisher
Aug 10, 2025

CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN

Aug 10, 2025
pulisher
Aug 10, 2025

Q3 EPS Estimate for CRISPR Therapeutics Boosted by Analyst - MarketBeat

Aug 10, 2025
pulisher
Aug 10, 2025

Leerink Partnrs Brokers Reduce Earnings Estimates for CRSP - MarketBeat

Aug 10, 2025
pulisher
Aug 09, 2025

CRISPR Therapeutics AG Insider Buying: Douglas Treco Acquires 20,000 Shares - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Given "Buy" Rating at Chardan Capital - MarketBeat

Aug 09, 2025

Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Crispr Therapeutics Ag Azioni (CRSP) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Treco Douglas A
Director
Aug 06 '25
Buy
57.03
20,000
1,140,600
22,000
George Simeon
Director
Jul 16 '25
Buy
52.03
989,812
51,499,918
1,730,179
Patel Naimish
Chief Medical Officer
May 29 '25
Sale
35.94
3,932
141,316
6,068
Kulkarni Samarth
Chief Executive Officer
Mar 21 '25
Sale
41.23
10,031
413,578
195,085
Bruno Julianne
Chief Operating Officer
Mar 21 '25
Sale
41.23
1,714
70,668
10,544
Prasad Raju
Chief Financial Officer
Mar 21 '25
Sale
41.23
2,197
90,582
16,767
KASINGER JAMES R.
General Counsel and Secretary
Mar 21 '25
Sale
41.23
3,185
131,318
81,729
Prasad Raju
Chief Financial Officer
Mar 17 '25
Sale
41.80
3,762
157,252
12,714
Kulkarni Samarth
Chief Executive Officer
Mar 11 '25
Sale
42.42
9,973
423,055
180,890
Kulkarni Samarth
Chief Executive Officer
Mar 12 '25
Sale
43.32
4,462
193,294
185,428
$24.31
price down icon 1.38%
$84.76
price down icon 0.33%
$26.27
price up icon 0.27%
$105.07
price down icon 5.24%
$128.32
price down icon 2.70%
biotechnology ONC
$308.63
price down icon 1.61%
Capitalizzazione:     |  Volume (24 ore):